Skip to main content
. 2008 Sep 20;2(4):416–428. doi: 10.1007/s12072-008-9100-3

Fig. 3.

Fig. 3

Potential pharmacologic targets for the treatment of ascites and hepatorenal syndrome in the nephron and splanchnic vascular territory and their pertinent receptors. α1, Alpha-adrenergic receptor; β1, Beta-adrenergic receptor; A1 and A2, Adenosine receptors 1 and 2; AldoR, Aldosterone receptor; AT1, Angiotensin-II receptor 1; ET-A, Endothelin receptor A: V1 and V2, Vasopressin receptors 1 and 2